Biotechnology firm Surrozen's Q3 net loss widens on higher R&D costs

Surrozen

07/11/2025 21:14

Overview

Surrozen Q3 net loss widens significantly year-over-year, with no collaboration revenue

Operating expenses increased due to higher R&D costs in ophthalmology programs

Company strengthens leadership with new CFO, Andrew Maleki, focusing on growth

Outlook

Company did not provide specific financial guidance for the current or future periods

Result Drivers

INCREASED R&D EXPENSES - R&D expenses rose due to higher manufacturing costs, lab expenses, and consulting fees for ophthalmology programs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$8.36
Q3 Net Income
-$71.64 mln
Q3 Operating Expenses
$11.87 mln
Q3 Operating Income
-$10.89 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Surrozen Inc is $37.00, about 66.2% above its November 6 closing price of $12.50

Press Release: ID:nGNX6RnHJ9

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)